Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001590750-25-000008
Filing Date
2025-05-06
Accepted
2025-05-06 07:55:45
Documents
75
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vrdn-20250331.htm   iXBRL 10-Q 1450993
2 EX-10.1 ex101_viridian-separationa.htm EX-10.1 112998
3 EX-10.3 ex103_viridian-executiveem.htm EX-10.3 92246
4 EX-31.1 ex311_2025-03.htm EX-31.1 11371
5 EX-31.2 ex312_2025-03.htm EX-31.2 12549
6 EX-32.1 ex321_2025-03.htm EX-32.1 9301
  Complete submission text file 0001590750-25-000008.txt   7868664

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vrdn-20250331.xsd EX-101.SCH 49525
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vrdn-20250331_cal.xml EX-101.CAL 62427
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vrdn-20250331_def.xml EX-101.DEF 341148
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vrdn-20250331_lab.xml EX-101.LAB 692201
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vrdn-20250331_pre.xml EX-101.PRE 499875
78 EXTRACTED XBRL INSTANCE DOCUMENT vrdn-20250331_htm.xml XML 900638
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36483 | Film No.: 25915291
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)